We performed in-depth validation of our CRISPR-Cas9 screen in independent isogenic cell clones of three different cell lines that clearly validated that lack of the NUDT18 paralog in chr8pLOH tumor cells sensitized them to NUDT17 ablation. This evidence concerns the gene NUDT17 and neoplasm.